Can nicotine be used medicinally in Parkinson's disease?
- PMID: 22114853
- DOI: 10.1586/ecp.11.27
Can nicotine be used medicinally in Parkinson's disease?
Abstract
The risk of Parkinson's disease is reduced by cigarette smoking, which raises some unanswered questions. Nicotine, a major component of tobacco smoke, could exert either nonreceptor-mediated biological effects or, more importantly, act on the different subtypes of nicotinic brain receptors, in particular those associated with the nigrostriatal dopaminergic pathway. There is now robust experimental evidence for a neuroprotective effect of nicotine upon dopaminergic neurons. By contrast, in animal models of Parkinson's disease, nicotine alone has slight or no motor effects. However, nicotine may modulate dopamine transmission and has clear motor effects when associated with L-DOPA, reducing L-DOPA-induced dyskinesias. Clinical trials have yielded inconclusive results thus far and are hampered by different designs and small cohorts. Ongoing studies address either symptomatic motor or nonmotor symptoms, or neuroprotection. There is still no agreement on the daily dosage of nicotine or the method of administration. Together, these data suggest that nicotine or nicotinic receptor drugs have therapeutic potential for Parkinson's disease, although the specific treatment regimens remain to be determined.
Similar articles
-
Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.Int Rev Neurobiol. 2015;124:247-71. doi: 10.1016/bs.irn.2015.07.005. Epub 2015 Aug 18. Int Rev Neurobiol. 2015. PMID: 26472532 Review.
-
Role of dopamine receptor agonists in the treatment of early Parkinson's disease.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S44-53. doi: 10.1016/S1353-8020(09)70835-1. Parkinsonism Relat Disord. 2009. PMID: 20123557 Review.
-
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].Rev Neurol (Paris). 2000 Mar;156(3):224-35. Rev Neurol (Paris). 2000. PMID: 10740093 Review. French.
-
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?Prog Neurobiol. 2011 Sep 1;94(4):389-407. doi: 10.1016/j.pneurobio.2011.06.005. Epub 2011 Jun 24. Prog Neurobiol. 2011. PMID: 21723913 Review.
-
Peculiarities of L: -DOPA treatment of Parkinson's disease.Amino Acids. 2005 Mar;28(2):157-64. doi: 10.1007/s00726-005-0162-4. Epub 2005 Mar 9. Amino Acids. 2005. PMID: 15750845 Review.
Cited by
-
Biologically Active Compounds Present in Tobacco Smoke: Potential Interactions Between Smoking and Mental Health.Front Neurosci. 2022 Apr 26;16:885489. doi: 10.3389/fnins.2022.885489. eCollection 2022. Front Neurosci. 2022. PMID: 35557609 Free PMC article. Review.
-
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease.Front Aging Neurosci. 2015 Jan 9;6:340. doi: 10.3389/fnagi.2014.00340. eCollection 2014. Front Aging Neurosci. 2015. PMID: 25620929 Free PMC article. Review.
-
Nicotine from cigarette smoking and diet and Parkinson disease: a review.Transl Neurodegener. 2017 Jul 2;6:18. doi: 10.1186/s40035-017-0090-8. eCollection 2017. Transl Neurodegener. 2017. PMID: 28680589 Free PMC article. Review.
-
Nicotine Has a Therapeutic Window of Effectiveness in a Drosophila melanogaster Model of Parkinson's Disease.Parkinsons Dis. 2022 Jul 8;2022:9291077. doi: 10.1155/2022/9291077. eCollection 2022. Parkinsons Dis. 2022. PMID: 35844833 Free PMC article.
-
Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.Psychopharmacology (Berl). 2013 May;227(2):331-45. doi: 10.1007/s00213-013-2973-4. Epub 2013 Feb 22. Psychopharmacology (Berl). 2013. PMID: 23430159 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical